- Trial phase
- Phase 3
- Time to market
- If Phase 3 TOPAZ trials succeed, Biogen would likely file a BLA in 2027, with potential FDA approval in 2028 at the earliest, given the drug is still in Phase 3 with no filed application.
- Why 7/10
- The next hard, dated catalyst is the Phase 3 TOPAZ-1 and TOPAZ-2 topline readout for systemic lupus erythematosus, expected in the first half of December 2026 (roughly 5-7 weeks from today). This is a pivotal binary readout on Biogen's first and most advanced lupus asset, making it a major value driver, but Biogen is a large-cap biotech with multiple approved products, so the drug is not the entire company thesis.
The next major catalyst is the Phase 3 TOPAZ-1 and TOPAZ-2 topline readout for systemic lupus erythematosus, expected in the first half of December 2026 (roughly 5-7 weeks away). Positive data would validate litifilimab across both CLE and SLE and likely trigger a significant stock rally; negative or mixed results would be a major setback for Biogen's first lupus program and could erase the stock's recent gains tied to pipeline optimism.
Price Chart
Executive Summary
Litifilimab (BIIB059) is Biogen's investigational first-in-class monoclonal antibody targeting BDCA2 for systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). It has shown positive Phase 2 results in both indications, including durable skin clearance through 52 weeks in CLE (27.2% clear/almost clear skin), and received FDA Breakthrough Therapy Designation for CLE in January 2026. The drug is not yet approved anywhere. The pivotal binary catalyst is the Phase 3 TOPAZ-1 and TOPAZ-2 topline readout for SLE, expected in the first half of December 2026, which will determine whether litifilimab can become a major new treatment option in a multi-billion-dollar market currently dominated by GSK's Benlysta and AstraZeneca's Saphnelo.
How It Works
Litifilimab is an injected antibody that targets a protein called BDCA2 found only on certain immune cells (plasmacytoid dendritic cells). By binding to BDCA2, it dials down the production of type I interferons and other inflammatory signals that are overactive in lupus, a chronic autoimmune disease where the immune system attacks the body's own tissues, causing skin rashes, joint pain, and organ damage.
Trial Status
Two Phase 3 trials in SLE (TOPAZ-1, NCT04895241; TOPAZ-2, NCT04961567) are fully enrolled with topline data expected December 2026. The Phase 2/3 AMETHYST study in CLE (NCT05531565) has completed its Phase 2 portion with positive 52-week results; the Phase 3 portion remains blinded and ongoing with readout guided for 1H 2027. A long-term extension study (NCT05352919) is also recruiting.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 TOPAZ-1 and TOPAZ-2 topline data for SLE: first half of December 2026
- Phase 3 AMETHYST CLE readout: first half of 2027
- Potential BLA submission if Phase 3 data are positive: 2027
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BIOGEN INC. 8-K BIIB ·Originating report